Literature DB >> 8499945

Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis.

E Legius1, D A Marchuk, F S Collins, T W Glover.   

Abstract

Individuals with neurofibromatosis type 1 (NF1) have an increased risk of developing benign and malignant tumours. The NF1 gene is thought to be a tumour suppressor gene, yet no direct proof at the molecular level exists to support this hypothesis. Here we describe a neurofibrosarcoma from a patient with NF1 with loss of heterozygosity for all chromosome 17 polymorphisms tested. On the remaining chromosome 17 homologue, a 200 kilobase (kb) tumour specific deletion of NF1 was demonstrated. This is the first example of a homozygous inactivation of NF1 at the molecular level in a malignant tumour from an NF1 patient and the results strongly support the tumour suppressor gene hypothesis for this disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8499945     DOI: 10.1038/ng0293-122

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  92 in total

1.  Schwann cell proliferative responses to cAMP and Nf1 are mediated by cyclin D1.

Authors:  H A Kim; N Ratner; T M Roberts; C D Stiles
Journal:  J Neurosci       Date:  2001-02-15       Impact factor: 6.167

Review 2.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

3.  NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors.

Authors:  A Perry; K A Roth; R Banerjee; C E Fuller; D H Gutmann
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

4.  Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.

Authors:  Trent R Hummel; Walter J Jessen; Shyra J Miller; Lan Kluwe; Victor F Mautner; Margaret R Wallace; Conxi Lázaro; Grier P Page; Paul F Worley; Bruce J Aronow; Elizabeth K Schorry; Nancy Ratner
Journal:  Clin Cancer Res       Date:  2010-08-25       Impact factor: 12.531

5.  Confirmation of a double-hit model for the NF1 gene in benign neurofibromas.

Authors:  E Serra; S Puig; D Otero; A Gaona; H Kruyer; E Ars; X Estivill; C Lázaro
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

6.  A search for evidence of somatic mutations in the NF1 gene.

Authors:  A M John; M Ruggieri; R Ferner; M Upadhyaya
Journal:  J Med Genet       Date:  2000-01       Impact factor: 6.318

7.  Mouse tumor model for neurofibromatosis type 1.

Authors:  K S Vogel; L J Klesse; S Velasco-Miguel; K Meyers; E J Rushing; L F Parada
Journal:  Science       Date:  1999-12-10       Impact factor: 47.728

Review 8.  Amino acid management in cancer.

Authors:  Zhi-Yang Tsun; Richard Possemato
Journal:  Semin Cell Dev Biol       Date:  2015-08-12       Impact factor: 7.727

9.  Surgery for Peripheral Nerve Sheath Tumours of the Buttocks, Legs and Feet in 90 Patients With Neurofibromatosis Type 1.

Authors:  Reinhard E Friedrich; Caglayan T Tuzcu
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

10.  Encephalocraniocutaneous lipomatosis with a mutation in the NF1 gene.

Authors:  E Legius; R Wu; M Eyssen; P Marynen; J P Fryns; J J Cassiman
Journal:  J Med Genet       Date:  1995-04       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.